Literature DB >> 21395602

Silybin inhibits interleukin-1β-induced production of pro-inflammatory mediators in canine hepatocyte cultures.

A Y Au1, J M Hasenwinkel, C G Frondoza.   

Abstract

Hepatocytes are highly susceptible to cytokine stimulation and are fundamental to liver function. We established primary canine hepatocyte cultures to study effects of anti-inflammatory agents with hepatoprotective properties. Hepatocyte cultures were incubated with control media alone, silybin (SB), or the more bioavailable silybin-phosphatidylcholine complex (SPC), followed by activation with interleukin-1 beta (IL-1β; 10 ng/mL). Inflammatory response was measured by prostaglandin E2 (PGE(2) ), interleukin-8 (IL-8), and monocyte chemotactic protein-1 (MCP-1) production and also nuclear factor-kappa B (NF-κB) translocation. Hepatocyte cultures continued production of the phenotypic marker albumin for more than 7 days in culture. IL-1β exposure increased PGE(2) , IL-8, and MCP-1 production, which was paralleled by NF-κB translocation from the cytoplasm to the nucleus. Pretreatment with SB and SPC significantly inhibited IL-1β-induced production of pro-inflammatory markers and attenuated NF-κB nuclear translocation. We demonstrate for the first time that primary canine hepatocyte cultures can be maintained in culture without phenotypic loss. The observation that hepatocyte cultures respond to pro-inflammatory IL-1β activation indicates hepatocytes as primary cellular targets of extrinsic IL-1β. The ability of SB and SPC to inhibit hepatocyte culture activation by IL-1β reinforces the notion of their hepatoprotective effects. Our primary canine hepatocyte culture model facilitates identification of hepatoprotective agents and their mechanism of action.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21395602     DOI: 10.1111/j.1365-2885.2010.01200.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  6 in total

Review 1.  Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Authors:  Tomas Koltai; Larry Fliegel
Journal:  J Evid Based Integr Med       Date:  2022 Jan-Dec

2.  Food-related compounds that modulate expression of inducible nitric oxide synthase may act as its inhibitors.

Authors:  Wilson Maldonado-Rojas; Jesus Olivero-Verbel
Journal:  Molecules       Date:  2012-07-05       Impact factor: 4.411

Review 3.  Evidences on Molecules Most Frequently Included in Canine and Feline Complementary Feed to Support Liver Function.

Authors:  Andrea Marchegiani; Alessandro Fruganti; Alessandra Gavazza; Sara Mangiaterra; Alessia Candellone; Eleonora Fusi; Giacomo Rossi; Matteo Cerquetella
Journal:  Vet Med Int       Date:  2020-05-09

4.  Effect of silibinin in reducing inflammatory pathways in in vitro and in vivo models of infection-induced preterm birth.

Authors:  Ratana Lim; Carrington J Morwood; Gillian Barker; Martha Lappas
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

5.  Silibinin protects against osteoarthritis through inhibiting the inflammatory response and cartilage matrix degradation in vitro and in vivo.

Authors:  Wenhao Zheng; Zhenhua Feng; Yiting Lou; Chunhui Chen; Chuanxu Zhang; Zhenyu Tao; Hang Li; Liang Cheng; Xiaozhou Ying
Journal:  Oncotarget       Date:  2017-08-24

6.  Evaluation of potential serum biomarkers of hepatic fibrosis and necroinflammatory activity in dogs with liver disease.

Authors:  Chantel Raghu; Joanne Ekena; John M Cullen; Craig B Webb; Lauren A Trepanier
Journal:  J Vet Intern Med       Date:  2018-02-27       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.